According to CSPC Innovation's announcement, the holding subsidiary Shiyao Group Jushi Biopharmaceutical Co., Ltd. recently received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the marketing application for envirastuzumab injection was accepted. Envirastuzumab injection is an antibody-conjugated drug targeting HER2. It is intended to treat unresectable or metastatic HER2-positive adult breast cancer patients who have previously been treated with one or more anti-HER2 drugs.

Zhitongcaijing · 1d ago
According to CSPC Innovation's announcement, the holding subsidiary Shiyao Group Jushi Biopharmaceutical Co., Ltd. recently received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the marketing application for envirastuzumab injection was accepted. Envirastuzumab injection is an antibody-conjugated drug targeting HER2. It is intended to treat unresectable or metastatic HER2-positive adult breast cancer patients who have previously been treated with one or more anti-HER2 drugs.